Monoxyde D’azote Sol France (Nitric Oxide)

Nitric oxide diffuses into the smooth muscle of pulmonary vessels and activates soluble guanylate cyclase. This raises cyclic GMP levels, which relaxes the muscle fibers, leading to selective dilation of the pulmonary arteries without significant systemic vasodilation.

The prescribed dose of inhaled nitric oxide is individualized by the treating physician based on the patient’s age, weight, severity of disease, and response to therapy. Clinicians set the concentration and duration according to clinical guidelines and monitoring results.

The safety of inhaled nitric oxide in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and decisions are made by the prescribing clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Inhaled nitric oxide offers rapid, selective pulmonary vasodilation with minimal systemic effects, unlike intravenous agents such as prostacyclin analogues that affect the whole circulatory system. Its short half‑life allows precise titration, but it requires specialized delivery equipment and monitoring.

Monoxyde D’azote Sol France should be stored at ambient temperature, below 25 °C, in its original cylinder packaging. Keep the container away from heat sources, direct sunlight and moisture. Ensure cylinders are secured upright to prevent damage.

The product is supplied as a medical‑grade gas cylinder. It is delivered to the patient through a calibrated inhalation system that mixes the gas with the ventilator circuit or breathing apparatus, allowing precise control of the inhaled concentration.

Serious risks include severe systemic hypotension, rebound pulmonary hypertension after abrupt discontinuation, significant methemoglobinemia, and rare neurotoxic events such as seizures. Continuous monitoring of blood pressure, methemoglobin levels and respiratory parameters is essential.

Patients with known hypersensitivity to nitric oxide, those with severe left‑heart dysfunction, uncontrolled systemic hypotension, or who are receiving other potent pulmonary vasodilators without close supervision should not be treated with inhaled nitric oxide.